Tofacitinib, an oral Janus kinase inhibitor (Jakinib), is an emerging treatment modality whose well-established efficacy in systemic inflammatory diseases is now being actively explored for cutaneous disorders (arising due to the patient's dysimmune responses) that are not responding to and/or sustaining intolerable adverse effects with the classical immunosuppressives and other targeted therapies such as the biologics. The most common dermatoses for which oral as well as topical Jakinibs such as tofacitinib have been evaluated and are being used albeit as an off-label indication include psoriasis, psoriatic arthritis, alopecia areata, vitiligo, and atopic dermatitis. This article provides a succinct review on the current status of oral tofacitinib in dermatology through literature search of PubMed database and stresses on the need for further evidence generation to define the drug's place in the therapeutic arsenal of dysimmune cutaneous disorders.
Introduction
Tofacitinib, an immunomodulator of Janus kinase inhibitor (Jakinib) family, blocks tyrosine kinases of the Janus family.
[1] Janus kinase-signal transducer and activator of transcription (JAK/STAT) is an intracellular pathway that drives downstream signaling of several pro-inflammatory pathways. The well-established efficacy of Jakinibs in inflammatory disorders, particularly rheumatoid arthritis (RA) and ulcerative colitis (UC), suggests the potential of their positive effects in a myriad of inflammatory dermatoses as well. [2] Jakinibs constitute an attractive and preferable option as a targeted therapy over biologics, owing to inhibition of signaling from multiple cytokines, unreported potential of generating neutralizing antibodies, and the ease of administration by oral and topical routes. [3] The aim of this paper is to provide a review of studies exploring their use (tofacitinib as the prototype) in dermatology.
Methods
A literature search was performed without the use of filters on PubMed with the following set of keywords: tofacitinib dermatology, tofacitinib skin disorders, JAK inhibitors dermatology, JAK inhibitors skin, tofacitinib psoriasis, tofacitinib psoriatic arthritis, tofacitinib alopecia, tofacitinib vitiligo, and tofacitinib atopic dermatitis. Articles from year 2001 to 2018 were reviewed, and 149 search results and their references were obtained. Criteria for consideration of search articles for inclusion purpose in the review were based on mutual decision of both the authors as per their relevance to the journal. After data extraction, information pertaining to the different subsections were processed and reorganized in the form of this narrative review. An attempt was made to objectivize the article by summarizing the content in tables.
Mechanism of action of tofacitinib: The JAK/STAT pathway
JAKs are intracellular enzymes that bind to the cytoplasmic domains of many cytokine receptors. The JAK/STAT signaling pathway is involved in many inflammatory skin diseases [ Figure 1 ], particularly those resulting from type I/II cytokine receptors-associated cytokines. [2] The major cutaneous and associated disorders that have shown the most promising results with tofacitinib and other Jakinibs include psoriasis and Indian Dermatology Online Journal | Volume 10 | Issue 5 | September-October 2019 psoriatic arthritis (PsA), alopecia areata (AA) and variants including AA totalis (AT) and AA universalis (AU), atopic dermatitis (AD), and vitiligo. [4] Anecdotal reports have also suggested their efficacy in cutaneous lupus erythematosus, dermatomyositis, chronic actinic dermatitis, erythema multiforme, hypereosinophilic syndrome, cutaneous graft-versus-host disease, pyoderma gangrenosum (PG), lichen planus, and Sjogren's syndrome, amongst others. [5] Types of Jakinibs Four JAK isoforms are known: JAK1, JAK2, JAK3, and TYK2. While JAK1, JAK2, and TYK2 bind to many cytokine receptors, JAK3 only binds one subunit, the common gamma chain. This shared receptor subunit is used by a small family of cytokines that includes interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21. While first-generation Jakinibs (tofacitinib, ruxolitinib, baricitinib) block multiple JAKs, the second generation (decernotinib, experimental agents such as VX-509, GLPG0634) target a particular JAK. [6] Specific Jakinibs are associated with less adverse events (AEs), particularly serious infections and cytopenias. Table 1 summarizes the current US Food and Drug Administration (FDA) approved indications of first-generation Jakinibs, with psoriatic arthritis representing the only skin-associated disorder for which oral tofacitinib is currently approved. [4] Second-generation Jakinibs are currently being evaluated in phase II studies. Tofacitinib, a JAK 1/3 inhibitor, is the most studied Jakinib in cutaneous diseases. As it blocks JAK2 only weakly, the JAK2-blockade associated hematological AEs are much lesser with this drug. [4] The key pharmacological concepts of tofacitinib [7] are detailed in Table 2 .
Clinical Use of Oral Tofacitinib in Skin Disorders: An Appraisal

Psoriasis
JAK/STAT-dependent cytokines IL-12 and IL-23 are principle mediators of psoriasis, the first cutaneous disease evaluated for treatment with tofacitinib. Their upstream blockade by tofacitinib indirectly decreases IL-17 levels.
[5] Results from multiple placebo-controlled and comparative randomized controlled trials (RCT) have established good efficacy of tofacitinib in psoriasis. [8] [9] [10] [11] [12] [13] [14] The therapeutic outcome with 5 or 10 mg tofacitinib was significantly better than placebo and comparable or superior to etanercept. [8] [9] [10] Results of a long-term extension study involving 2867 psoriatic patients who were administered tofacitinib 5-10 mg twice daily as per a specific protocol of more than three months showed that 52-62% patients achieved 75% improvement in Psoriasis Area and Severity Index (PASI75) through month 54. General and serious AEs were reported in 82.5% and 13.7% patients, respectively; 13.9% discontinued the drug owing to AEs. Twenty-nine deaths occurred during the study, of which nine were considered potentially related to tofacitinib, malignancy being the most common cause. [12] In an aggregate data model-based meta-analysis that quantitatively evaluated the time-course and treatment effects of systemic agents for psoriasis, tofacitinib 10 mg twice daily showed PASI75 and PASI90 response rates comparable to cyclosporine, noninferior or better than methotrexate and better than acitretin and apremilast. [14] 
Psoriatic arthritis
PsA is a US FDA-approved indication of oral tofacitinib with evidence of efficacy of tofacitinib being better than placebo and comparable to adalimumab. [15] The drug also showed improvement in patients not responding despite 6 months treatment with at least one TNF-α inhibitor. [16] Although results were better with the higher dose (10 mg twice-a-day), 5 mg twice daily is currently the preferred dose for PsA owing to better safety. [17] 
Alopecia areata
The serendipitous discovery of tofacitinib as a treatment for AA led to further exploration. [18] JAK-STAT-dependent cytokines interferon (IFN)-γ and IL-15 drive activation of autoreactive CD8 T cells that are crucial in the pathogenesis of AA. [5] Improvement of >50% in Severity of Alopecia Tool (SALT) score has been reported in 32-66% patients treated with tofacitinib. [19] [20] [21] The efficacy varies with disease severity, drug dosage, and adjuvant treatments. Better overall outcomes were reported in patchy AA (versus AT/ AU), with 10 mg twice daily (instead of 5 mg twice daily), and with concomitant oral steroids. [20, 21] Relapses were frequent but responded to higher doses and/or corticosteroid addition. [20] The well-known waxing-and-waning and relapsing course of severe variants of AA such as AT and AU (despite the use of tofacitinib) mandates thorough pretreatment counseling of the patient and/or guardians about the possibility of waning treatment response, possible need for dosage increment, and unpredictability of relapse following cessation of therapy. [22] Tofacitinib has been reported to provide similar efficacy as oral ruxolitinib, higher efficacy than contact immunotherapy, and better tolerability than conventional immunosuppressive treatments (corticosteroids ± cyclosporine) in AA. [23, 24] In addition, the drug has demonstrated improvement in nail symptoms of AA. [25] The longest reported duration of treatment with tofacitinib in AA/AT/AU is 18 months. [20, 21] 
Vitiligo
Tofacitinib inhibits IFN-γ signaling, which drives the CD8 T cell-mediated melanocyte destruction. [5] Satisfactory re-pigmentation has been reported with 5-10 mg twice daily, [26] with better outcome seen in sun-exposed areas and concomitant narrowband ultraviolet B (NB-UVB) therapy. [27, 28] 
Atopic dermatitis
Tofacitinib decreases IL-4, IL-5, and IL-13 signaling involved in the pathogenesis of AD. [5, 29, 30] It additionally reduces AD-associated pruritus, because JAK signaling in nerves critically regulates AD-associated itch. [31] 
Other dermatoses
Recent anecdotal reports and short case series have demonstrated efficacy of tofacitinib in certain other cutaneous disorders as well. Oral tofacitinib 5-10 mg twice daily given to three patients with Crohn's disease (primarily for associated severe inflammatory arthritis) and PG refractory to biologics, resulted in resolution of all PG lesions in 12 weeks. [32] Oral tofacitinib 5 mg two to three times daily given for 2-19 months in combination with other immunomodulatory therapies such as low-dose methotrexate reportedly produced significant improvement in patients with generalized deep morphea and eosinophilic fasciitis nonresponsive to corticosteroids, and in patients with treatment-recalcitrant lichen planopilaris. [33, 34] A review of major studies evaluating the efficacy and safety of oral tofacitinib in specific dermatoses is detailed in Table 3 .
Oral versus Topical Tofacitinib
The AEs associated with oral Jakinibs may be offset with their topical formulations. Topical tofacitinib (TT), most commonly used as a 2% ointment with/without penetration enhancers, demonstrated modest improvement in psoriasis and AD. [35] In psoriasis, lower concentrations (0.02, 0.2, and 1%) showed efficacy comparable to 2% formulation.
[36] In a 24-week, open-label pilot study of 10 patients with AA treated with tofacitinib 2% ointment applied twice daily, 3 patients experienced hair regrowth with a mean decrease of 34.6% in SALT score. The response was less than oral tofacitinib but similar to that reported with clobetasol 0.05% ointment under occlusion. [37] Although results in AA/AT/AU have been modest and conflicting, [35] TT may be a favorable treatment option to induce hair regrowth in locations such as eyebrows and eyelashes. A near complete regrowth of eyelashes was reported with tofacitinib 2% solution by 4 months in a patient who had used multiple ineffective prior modalities. [38] At the time of authoring this review, [9] Moderate-to-severe chronic plaque psoriasis [10] Moderate to severe plaque psoriasis Phase 3, placebo-controlled RCT 1092 patients.
Randomization and intervention details:
Patients randomly divided in a 3:3:3:1 ratio into four groups: PtGA response rate significantly greater with tofacitinib 10 mg versus placebo Lloyd-Lavery 2018 [11] (Linked artice: Valenzuela et al.) [12] Moderate to severe chronic plaque psoriasis
Multiple phase 2 and global phase 3 trials with open-label long-term extension (LTE) study
patients
Intervention details and duration of therapy:
Patients received tofacitinib 10 mg BD for 3 months followed by 5-10 mg BD for a median duration of 35.6 months Longest efficacy and safety data reported up to month 66 The majority of cases of herpes zoster were nonserious, were of mild or moderate severity and resolved on treatment. Serious infections and herpes zoster were numerically higher with tofacitinib 10 mg BD than with 5 mg BD; but were below that reported in some studies for tumor necrosis factor antagonists Checchio et al. 2017 [14] Moderate to severe psoriasis Aggregate data model-based meta-analysis Evaluation of the magnitude and onset of the drug effect by two mathematical models: (1) Longitudinal model to quantify the time course of PASI75.
2) Landmark model to quantify the dose-response relationship for PASI responders (PASI50, PASI75, PASI90, PASI100) at week 12 [16] PsA with an inadequate response to at least one TNF-α inhibitor for 6 months Double-blind, active, and placebo-controlled, phase 3 RCT-OPAL BROADEN study (Oral Psoriatic Arthritis trial) [24] AT and AU Hair regrowth on all of the affected body parts
Randomization and intervention details: Patients randomized in a 2:2:2:1:1 ratio into five groups: Tofacitinib 5 mg BD Tofacitinib 10 mg BD Adalimumab 40 mg once every 2 weeks (subcutaneous) Placebo with a blinded switch to either 5 or 10 mg tofacitinib at 3 months Duration of therapyhair shedding occurred after treatment completion, but three of the eight responders, maintained lower SALT scores compared to baseline at nearly 24 weeks off tofacitinib Most common AEs-URTI AE leading to treatment discontinuation-Hypertensive urgency in 1 patient with prior history of hypertension, at 12 weeks of treatment No major laboratory abnormalities. Treatment discontinuation in 1 patient-persistent 1 + blood on urinalysis Almutairi et al. 2018 [23] AA with>30% scalp hair loss, AT and AU Open-label comparative study 75 patients Intervention details: Patients randomized into two groups: Oral ruxolitinib 20 mg BD Oral tofacitinib 5 mg BD Duration of therapy: 6-months followed by 3 months of follow-up off therapy. Outcome measures: Change in SALT score Mean change in SALT score: 93.8+3.25 in ruxolitinib group 95.2+2.69 in tofacitinib group Duration for initial hair regrowth-shorter in ruxolitinib group Overall hair regrowth-remarkable and statistically similar in both groups at the end of 6 months treatment Relapse rate at the end of the 3-month follow-up-around two-thirds of cases experienced relapse in both groups Both drugs were well tolerated, with no reported serious adverse effects Most common AEs noted (both groups)-leukopenia, acute infections, mild raise in liver enzymes, dyslipidemia Shin et al. 2019
No AEs or laboratory abnormalities
RCT=Randomized controlled trial, OD=Once-a-day, BD=Twice-a-day, PASI75: >75% reduction in Psoriasis Area and Severity Index, PGA=Physician's Global Assessment, AEs=Adverse effects, LDL=Low-density lipoprotein, HDL=High-density lipoprotein, CPK=Creatinine phosphokinase, PROs=Patient reported outcomes, DLQI=Dermatology Life Quality Index, ISIS=Itch severity item score, PtGA=Patient's Global Assessment, LTE=Long-term extension, URTI=Upper respiratory tract infection, MACEs=Major adverse cardiovascular events, TNF-α=Tumor necrosis factor-α, ACR20=American College of Rheumatology 20 response (≥20% improvement from baseline in the number of tender and swollen joints and at least three of five other important domains), HAQ-DI=Health Assessment Questionnaire-Disability Index score (ranging from 0 to 3, with higher scores indicating greater disability), PsA=Psoriatic arthritis, DMARD=Disease modifying antirheumatic drugs, AA=Alopecia areata, AT=Alopecia totalis, AU=Alopecia universalis, SALT score=Severity of Alopecia Tool, DPCP=Diphenylcyclopropenone, BSA=Body surface area, NB-UVB=Narrow band ultraviolet B, AD=Atopic dermatitis, SCORAD=Scoring of Atopic Dermatitis, EASI=Eczema Area and Severity Index there was no report published in indexed literature of TT in vitiligo, although topical ruxolitinib demonstrated decent efficacy in facial lesions of vitiligo. [39] The vehicle of the topical formulation impacts the efficacy; better results were reported with liposomal-based TT. [40] The most common AEs seen with TT were erythema, hyperpigmentation, transient acne, and minor and reversible laboratory abnormalities. [35] A succinct review on the current status of topical Jakinibs for inflammatory dermatoses is advised for further reading for interested readers. [35] 
Use in Specific Populations
The use of oral tofacitinib in special populations [2, 7, [41] [42] [43] has been summarized in Table 4 .
AEs reported with oral tofacitinib
The six major groups of AEs [1] associated with tofacitinib that dermatologists should be aware and vigilant about have been summarized in Table 5 and include: 1. Infections: Cutaneous/Systemic; new onset/reactivation of latent infections; nasopharyngitis/severe infections; opportunistic infections (OIs) 2. Malignancies: Solid organ cancers, lymphoproliferative malignancies including lymphomas, cutaneous including nonmelanoma skin cancers (NMSC) and melanoma [17] 3. Gastrointestinal: Gastrointestinal perforations and obstruction [7] 4. Laboratory abnormalities: Hematological, liver derangement with enzyme elevations, dyslipidemia 5. Hypersensitivity reactions and miscellaneous: Urticaria, angioedema, headache, [44] hypertension, [12] distal symmetric polyneuropathy, and musculoskeletal complaints such as arthralgia, back pain, and pain in extremities [17] 6. Drug interactions: As such tofacitinib does not cause any significant inhibition or induction of the major human drug-metabolizing Cytochrome P450s (CYPs), but its pharmacokinetics and effects/adverse effects may be altered by drugs affecting CYP isoforms. The important drug interactions [7] that must be known to a dermatologist prescribing oral tofacitinib have been mentioned in Table 6 .
Inhibition of multiple JAKs by tofacitinib suggests a high risk for infections and malignancies. [5] Interestingly, clinically observed toxicity is limited, probably attributable to rapid kinetics of action. [3] The most common AEs reported with oral tofacitinib include upper respiratory tract infections, headache, diarrhea, and reactivation of viral infections (particularly herpes zoster). Risk of disseminated disease and serious infections is more with higher dose (10 mg BD) and with concomitant immunomodulators (methotrexate or corticosteroids) necessitating more cautious monitoring. [4] Reactivation of latent tuberculosis (TB) infection (LTBI) has been reported in patients with systemic inflammatory disorders such as RA. [7, 45] India is endemic for TB and one of the high background TB incidence rate (IR) countries (TB IR >0.05/100 patient-years). As per a review of phases II and III and long-term extension clinical trial data from the tofacitinib RA program, 26 out of 5675 RA patients (0.45%) on tofacitinib (phase II studies) developed active TB as an OI. Of these 26 patients, 21 (81%) belonged to TB-endemic countries like India. [46] Majority of cases developed in patients treated with high doses (10 mg BD). Secondly, of the phase III study cohort, 263 patients were diagnosed with LTBI by one of the following LTBI screening tests-QuantiFERON-TB Gold In-Tube (QFT-IT; Quest Diagnostics) or tuberculin Pregnancy outcomes analyzed in patients with rheumatoid arthritis or psoriasis treated with oral tofacitinib were similar to those in the general population and patients treated with biologic therapies [41] Oral tofacitinib is a pregnancy category C drug-safety in pregnancy is not well established and should be used only if benefits outweigh the potential risks [7] Lactation The drug is secreted in breast milk. To avoid exposure to the feeding infant, breastfeeding should be avoided during and for a duration of six elimination half-lives of the drug and its formulation
Breastfeeding is best avoided during treatment and for at least 18 h after the last dose (36 h after the last dose of the extended release formulation) [7] Pediatric population Evidence is not robust. A study conducted for AA in 13 adolescents (aged 12-17 years), treated with tofacitinib 5 mg twice daily for 2-16 months showed good efficacy and no serious AEs. [42] In a case series of four preadolescent children with AA, treated with oral tofacitinib 5 mg twice daily, good response was seen, and no AEs were noted over 6-15 months [43] Benefit-risk should be discussed with the child's parents/guardians before starting therapy since safety in individuals less than 18 years of age is not confirmed [2] Geriatric population Evidence is not robust
Higher incidence of infectious events reported in the elderly patients treated with oral tofacitinib [7] Benefit-risk should be discussed with the patient and caregivers before starting therapy since safety remains to be established Cutaneous Others Infections (including activation/ re-activation of latent/remitted infections) [1] Herpes zoster
Reactivation of herpes simplex
Upper respiratory tract infections, nasopharyngitis Urinary tract infections Opportunistic infections Activation of latent tuberculosis Pulmonary cryptococcosis Histoplasmosis Reactivation of a past hepatitis B infection Malignancy [17] 
NMSC Melanoma
Cancers of prostate, lungs, breast, pancreas Lymphomas and EBV-induced lymphoproliferative disorders Gastrointestinal [7] Gastrointestinal perforations-especially in patients with diverticulitis, on concomitant NSAIDs or corticosteroids With preexisting severe gastrointestinal narrowing (pathologic or iatrogenic) Gastrointestinal obstruction-rare, but risk with XR preparation in patients with preexisting severe gastrointestinal narrowing (pathologic or iatrogenic) Laboratory abnormalities [1] Hematological-reversible dose-dependent decrease in hemoglobin levels, RBC count, absolute neutrophil counts, and absolute lymphocyte count Enzyme elevations-dose-dependent increase in SGPT, SGOT, CPK Dyslipidemia-dose-dependent elevation in HDL, LDL, and total cholesterol levels, TG levels Hypersensitivity and miscellaneous Urticaria [44] Angioedema Rash Headache Distal symmetric polyneuropathy [1] Hypertension [12] Musculoskeletal issues such as arthralgia, back pain, pain in extremities [17] EBV=Epstein Barr virus, NSAIDs=Nonsteroidal antiinflammatory drugs, XR=Extended release, RBC=Red blood cell, SGPT=Serum glutamic pyruvic transaminase, SGOT=Serum glutamic oxaloacetic transaminase, CPK=Creatinine phosphokinase, HDL=High-density lipoprotein, LDL=Low-density lipoprotein, TG=Triglyceride skin test (TST; positive if induration ≥5 mm), and all of them received concomitant Isoniazid (INH) prophylaxis that guarded them from developing active TB. Also, while tofacitinib-treated patients using INH were slightly more likely to develop small elevations in liver enzymes during therapy, they were no more likely to develop significant liver transaminases elevation (>3× upper limit of normal) during therapy than tofacitinib-treated patients not using INH. [46] However, it is important to note that active TB with/ without prior LTBI has till now not been reported as an AE of tofacitinib treatment for any dermatoses from India or the globe. [2] Although speculative, this dichotomy may result from many factors-overall less pool of patients treated till now (compared to RA), lack of screening for LTBI, lack of active surveillance for active TB during and after treatment, reporting bias, lower doses and treatment duration used relative to RA, lesser incidence of the use of concomitant immunomodulatory therapies, higher doses, and the fact that majority of the published studies on tofacitinib use for skin disorders hail from TB-nonendemic and low TB IR countries. Thus, it may be premature to comment on this risk any further as of now. Till then, the recommended guidelines of pretreatment evaluation for latent and active TB and administration of INH treatment (if required) with annual screening for TB should be followed in all patients planned for oral tofacitinib treatment for any skin disorder. [12] Table 7 summarizes the current recommendations regarding the risk of latent/active TB and use of oral tofacitinib.
Malignancies, most commonly cancers involving the prostate, lungs, breast, and NMSC have been reported in tofacitinib studies, with the risk being comparable to that observed with other targeted immunosuppressive therapies. [11, 47] Lymphomas and Epstein Barr virus-associated posttransplant lymphoproliferative disorders have been observed at an increased rate in renal transplant patients treated with tofacitinib and concomitant immunosuppressive medications. [4] Targeted screening with personal and family history of malignancy, including NMSC and other risk factors such as past treatment with UVB, merits consideration in high-risk patients before tofacitinib administration. [17] Long-term studies are warranted to evaluate the specific risk of malignancy induction with oral tofacitinib in cutaneous disorders.
Gastrointestinal perforation has been reported; risk factors being history of diverticulitis, concomitant intake of nonsteroidal antiinflammatory drugs, oral corticosteroids. Although rare, there is a possibility of gastrointestinal obstruction due to the nondeformable XR preparation in patients with preexisting severe pathologic or iatrogenic gastrointestinal narrowing. [7] Laboratory derangements may occur. Cytopenias are generally not common with tofacitinib (due to weak JAK2 inhibition), particularly in patients with healthy bone marrow reserves. [4] However, anemia, and fall in red blood cells, neutrophil and lymphocyte counts have been reported in studies of tofacitinib given for RA and UC. Elevations in creatine phosphokinase enzyme and liver enzymes (transaminases) greater than three times the upper limit of normal have been observed in patients treated with tofacitinib. Dyslipidemia with minor elevations in low-density lipoprotein, high-density lipoprotein, and total cholesterol and serum triglyceride levels are well known with this drug. Despite an increased risk of hypertension and dyslipidemia, an increased risk of major adverse cardiovascular events has not been reported. [12] Tofacitinib-induced hyperlipidemia may last for up to 12 weeks followed by stabilization. Persistent hyperlipidemia should be treated as per standard clinical guidelines, e.g., National Cholesterol Educational Program Table 6 : Important drug interactions of oral tofacitinib [7] As such tofacitinib does not cause any significant inhibition or induction of the major human drug-metabolizing CYPs, but its pharmacokinetics and effects/adverse effects may be altered by other drugs affecting CYP isoforms as detailed below Strong CYP3A4 inhibitor(s) (e.g., ketoconazole) OR moderate CYP3A4 inhibitor (s) with strong CYP2C19 inhibitor(s) (e.g., fluconazole)
Pharmacological effect Reduced metabolism leading to increased serum levels of tofacitinib Intervention Dosage reduction, e.g., from 5 mg BD or 11 mg XR OD to 5 mg OD Strong CYP3A4 inducers (e.g., rifampin)
Pharmacological effect Increased metabolism leading to increased serum levels of tofacitinib
Additive hepatotoxicity Intervention
Co-administration is not recommended by the innovator. Also, risk of hepatic dysfunction will be more Immunosuppressive Drugs (e.g., azathioprine, tacrolimus, cyclosporine)
Pharmacological effect Co-administration to be avoided owing to increased risk of immunosuppression Intervention Co-administration is not recommended Coadministration with biologics, DMARDs or other potent immunosuppressants Pharmacological effect Not well-studied. Theoretical risk of added immunosuppression Intervention Co-administration not recommended DMARD=Disease-modifying anti-rheumatic drugs (such as hydroxychloroquine, sulfones) (NCEP). Use of lipid lowering agents such as statins improves the dyslipidemia, although regular monitoring of hepatic enzymes becomes mandatory in such cases. [17] Drug hypersensitivity presenting as angioedema and urticaria have been observed in post marketing experience. [44] Dose-dependent adverse reactions (seen more in patients treated with 10 mg twice daily than 5 mg twice daily) include herpes zoster infections, serious infections, and malignancy induction, particularly NMSC. [17] 
Contraindications and Precautions
While there are no contraindications for tofacitinib per se, in Table 8 we have listed conditions in which treatment should not be initiated (may be construed as "absolute contraindications"), conditions in which tofacitinib should preferably be started if the required benefit outweighs the risk (may be construed as "relative contraindications"-treatment may be given but only after discussion about possible adverse issues with the patient and with extra cautious and close clinical and/or laboratory monitoring), and situations that warrant temporary or permanent interruption of the treatment. [7] Table 9 summarizes the recommended guidelines for monitoring treatment with oral tofacitinib, independent of therapeutic indication. [4, 7, 44] Table 10 describes the Child-Pugh Score, to be applied for monitoring patients with hepatic impairment. Patients treated with XELJANZ 5 mg twice daily may be switched to XELJANZ XR 11 mg once daily, the day following the last dose of XELJANZ 5 mg. [7] 
Availability in India
Conclusion
Based on current literature, tofacitinib holds a significant potential to broaden the treatment options for many chronic inflammatory dermatoses with unmet medical needs. Although the absence of data on long-term efficacy, frequent post-cessation relapses, inadequately evaluated safety issues, and high cost limit its use, the drug's ability to induce rapid improvement and the reported clinical toxicity being much lesser than the predicted potential have added tofacitinib and its congeners to the ever-expanding therapeutic armamentarium of inflammatory dermatoses. Multicentric well-designed controlled studies are needed to address the gaps regarding the ideal dosing, treatment duration, and safety profile of tofacitinib. Innovative research in development of better topical formulations and more selective Jakinibs offer the potential of harnessing better efficacy with lesser AEs. Patients should be evaluated and tested for latent or active infection prior to drug initiation and then annually.
Tests that may be used for LTBI screening-QuantiFERON-TB Gold In-Tube (QFT-IT), Mantoux tuberculin skin test (TST)*, chest X-ray.
Additional tests that may be considered if the above are negative and/or there is suspicion of active TB (individualized for each case)-clinical review to look for a source of EPTB such as enlarged lymph nodes, sputum analysis with AFB staining and mycobacterial culture, ultrasonography and/or CT-scan of abdomen and pelvis, endometrial brushing in women, etc.
Anti-tuberculosis therapy should be strongly considered prior to drug administration in patients: [7] With past history of latent or active TB in whom an adequate course of treatment cannot be confirmed With a negative test for latent TB but who have risk factors for TB infection.
Patients confirmed with active TB should not be treated with tofacitinib; rather first treated with multidrug ATT as per the nation's recommended protocol.
Isoniazid therapy should be concomitantly given to any patient who is diagnosed with LTBI with preferably 1 month of isoniazid prior to starting tofacitinib and complete 9 months regime thereafter. In view of modest risk of transaminitis, more frequent liver enzyme monitoring may be considered in these patients. [46] Consider consultation with a TB specialist regarding decision about initiating anti-tuberculosis therapy in an individual patient.
Close monitoring for development of signs and symptoms of TB is warranted, even in patients who tested negative for latent TB prior to initiating therapy. LTBI=Latent tuberculosis infection, TB=Tuberculosis, EPTB=Extra-pulmonary tuberculosis, AFB=Acid-fast bacilli, ATT=Antitubercular therapy. *TST should be conducted as per the national health program recommendation, e.g., in India, as per the latest guidelines of the Revised National TB Control Programme (RNTCP, 2016). 0.1 ml of 2TU/5TU given intradermally over the volar aspect of the forearm, induration ≥10 mm at 48-72 h considered POSITIVE Immunizations done prior to initiating therapy (impaired response to vaccination). Use of live vaccines concurrently with tofacitinib not recommended. They should be administered at least 2 weeks, preferably 4 weeks prior to drug initiation [44] CBC=Complete blood count, LFT=Liver function test, CPK=Creatinine phosphokinase, HIV=Human immunodeficiency virus, TB=Tuberculosis, IFN-γ=Interferon-γ, OD=Once-a-day, XR=extended release. *Treatment not initiated if: Absolute lymphocyte count <500/mm 3 or absolute neutrophil count (ANC) <1000/mm 3 or hemoglobin <9 g/dL. † Moderate and severe renal insufficiency-creatinine clearance 30-49 mL/min and <30 mL/min, respectively. ‡ Moderate hepatic impairment-Child-Pugh score Grade B (7-9 points) 
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